Hostname: page-component-7b7567c8c-fvjsw Total loading time: 0 Render date: 2026-11-17T12:12:48.478Z Has data issue: false hasContentIssue false

Should We Pay for Scientific Knowledge Spillovers? The Underappreciated Value of “Failed” R&D Efforts

Published online by Cambridge University Press:  17 March 2022

Richard Z. Xie*
Affiliation:
The Innovation and Value Initiative, Alexandria, VA, USA
Adrian Towse
Affiliation:
Office of Health Economics, London, United Kingdom
Louis P. Garrison Jr.
Affiliation:
The Comparative Health Outcomes, Policy, and Economics (CHOICE) Institute, University of Washington, Seattle, WA, USA
*
*Author for correspondence: Richard Z. Xie, E-mail: richard.xie@thevalueinitiative.org
Rights & Permissions [Opens in a new window]

Abstract

Recent experience with COVID-19 has reminded us of the importance of scientific progress in enabling pharmaceutical innovation. Developing novel therapies is a highly risky but rewarding process: it not only produces innovative drugs, but also valuable scientific knowledge that benefits the community of innovators. This paper examines whether the existing reward system for pharmaceutical research and development (R&D) leads to socially optimal levels of scientific knowledge generation and sharing, with a particular focus on the value of failures in the pharmaceutical R&D efforts. We first outline a conceptual approach based on the idea that pharmaceutical R&D efforts produce both medicines and scientific knowledge, and illustrate this with some examples of how failures may generate information beneficial to concurrent and subsequent R&D efforts. We then summarize the relatively small literature on failures in pharmaceutical R&D and their impact on R&D decision making. Lastly, we discuss several market-based and nonmarket-based policy approaches that can address potential shortcomings in the current reward system which may lead to suboptimal R&D and knowledge sharing.

Information

Type
Article Commentary
Creative Commons
Creative Common License - CCCreative Common License - BY
This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (http://creativecommons.org/licenses/by/4.0), which permits unrestricted re-use, distribution and reproduction, provided the original article is properly cited.
Copyright
© The Author(s), 2022. Published by Cambridge University Press
Figure 0

Figure 1.Scientific knowledge spillovers: examples from R&D on a novel mechanism of action.

Figure 1

Table 1.Examples of Scientific Knowledge Spillovers from Failed R&D Efforts

Supplementary material: PDF

Xie et al. supplementary material

Xie et al. supplementary material

Download Xie et al. supplementary material(PDF)
PDF 110.7 KB